Pharmaceutical Manufacturing · Auvergne-Rhône-Alpes
Aíma develops advanced liquid biopsy tests for minimal residual disease and early cancer detection. Our whole-genome methylation and fragmentomics platform combines AI with ultra-sensitive sequencing to detect cancer DNA and determine its tissue of origin. We collaborate with leading clinical centers to bring faster, more accurate and more accessible cancer diagnostics to patients.